FDA
-
-
-
-
-
-
-
HCW Biologics reports positive primate study results for T-cell engager
-
-
-
-
-
-
-
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results
-
-
-
-
-
-
-
HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
-
-
-
-
-
-
-
HCW Biologics (HCWB) Announces U.S. Patent Issued for Foundational Platform Technology
-
-
-
-
-
-
-
HCW Biologics’ CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022
-
-
-
-
-
-
-
Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics’ Novel Bifunctional Fusion Protein
-
-
-
-
-
-
-
HCW Biologics to Participate in H.C. Wainwright BioConnect Conference January 10 – 13, 2022
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

